The Role of 68Ga-FAPI PET/CT in Detection of Metastatic Lobular Breast Cancer

Yael Eshet; Noam Tau; Sara Apter; Noam Nissan; Keren Levanon; Rinat Bernstein-Molho; Ofer Globus; Amit Itay; Tal Shapira; Cecilie Oedegaard; Malka Gorfine; Michal Eifer; Tima Davidson; Einav Gal-Yam; Liran Domachevsky

doi:10.1097/RLU.0000000000004540

The Role of ⁶⁸Ga-FAPI PET/CT in Detection of Metastatic Lobular Breast Cancer

Yael Eshet^*, Noam Tau, Sara Apter, Noam Nissan, Keren Levanon, Rinat Bernstein-Molho, Ofer Globus, Amit Itay, Tal Shapira, Cecilie Oedegaard, Malka Gorfine, Michal Eifer, Tima Davidson, Einav Gal-Yam, Liran Domachevsky

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

Purpose Invasive lobular breast cancer (ILC) may be hard to detect using conventional imaging modalities and usually shows less avidity to 18F-FDG PET/CT. 68Ga-fibroblast activation protein inhibitor (FAPI) PET/CT has shown promising results in detecting non-18F-FDG-avid cancers. We aimed to assess the feasibility of detecting metastatic disease in patients with non-18F-FDG-avid ILC. Methods This prospective study included patients with metastatic ILC, infiltrative to soft tissues, which was not 18F-FDG avid. The patients underwent 68Ga-FAPI PET/CT for evaluation, which was correlated with the fully diagnostic CT performed at the same time. Results Seven women (aged 57 ± 10 years) were included. Among the 30 organs and structures found to be involved by tumor, the number of findings observed by FAPI PET/CT was significantly higher than that observed by CT alone (P = 0.022), especially in infiltrative soft tissue and serosal locations. Conclusions This small pilot trial suggests a role for 68Ga-FAPI PET/CT in ILC, which needs to be confirmed by subsequent trials.

Original language	English
Pages (from-to)	228-232
Number of pages	5
Journal	Clinical Nuclear Medicine
Volume	48
Issue number	3
DOIs	https://doi.org/10.1097/RLU.0000000000004540
State	Published - 1 Mar 2023

Keywords

FAPI-04
PET/CT
breast neoplasms
carcinoma
lobular

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/RLU.0000000000004540

Cite this

Eshet, Y., Tau, N., Apter, S., Nissan, N., Levanon, K., Bernstein-Molho, R., Globus, O., Itay, A., Shapira, T., Oedegaard, C., Gorfine, M., Eifer, M., Davidson, T., Gal-Yam, E., & Domachevsky, L. (2023). The Role of ⁶⁸Ga-FAPI PET/CT in Detection of Metastatic Lobular Breast Cancer. Clinical Nuclear Medicine, 48(3), 228-232. https://doi.org/10.1097/RLU.0000000000004540

@article{81c565e7b00b4be0bd08ee760e68fd90,

title = "The Role of 68Ga-FAPI PET/CT in Detection of Metastatic Lobular Breast Cancer",

abstract = "Purpose Invasive lobular breast cancer (ILC) may be hard to detect using conventional imaging modalities and usually shows less avidity to 18F-FDG PET/CT. 68Ga-fibroblast activation protein inhibitor (FAPI) PET/CT has shown promising results in detecting non-18F-FDG-avid cancers. We aimed to assess the feasibility of detecting metastatic disease in patients with non-18F-FDG-avid ILC. Methods This prospective study included patients with metastatic ILC, infiltrative to soft tissues, which was not 18F-FDG avid. The patients underwent 68Ga-FAPI PET/CT for evaluation, which was correlated with the fully diagnostic CT performed at the same time. Results Seven women (aged 57 ± 10 years) were included. Among the 30 organs and structures found to be involved by tumor, the number of findings observed by FAPI PET/CT was significantly higher than that observed by CT alone (P = 0.022), especially in infiltrative soft tissue and serosal locations. Conclusions This small pilot trial suggests a role for 68Ga-FAPI PET/CT in ILC, which needs to be confirmed by subsequent trials.",

keywords = "FAPI-04, PET/CT, breast neoplasms, carcinoma, lobular",

author = "Yael Eshet and Noam Tau and Sara Apter and Noam Nissan and Keren Levanon and Rinat Bernstein-Molho and Ofer Globus and Amit Itay and Tal Shapira and Cecilie Oedegaard and Malka Gorfine and Michal Eifer and Tima Davidson and Einav Gal-Yam and Liran Domachevsky",

year = "2023",

month = mar,

day = "1",

doi = "10.1097/RLU.0000000000004540",

language = "אנגלית",

volume = "48",

pages = "228--232",

journal = "Clinical Nuclear Medicine",

issn = "0363-9762",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "3",

}

TY - JOUR

T1 - The Role of 68Ga-FAPI PET/CT in Detection of Metastatic Lobular Breast Cancer

AU - Eshet, Yael

AU - Tau, Noam

AU - Apter, Sara

AU - Nissan, Noam

AU - Levanon, Keren

AU - Bernstein-Molho, Rinat

AU - Globus, Ofer

AU - Itay, Amit

AU - Shapira, Tal

AU - Oedegaard, Cecilie

AU - Gorfine, Malka

AU - Eifer, Michal

AU - Davidson, Tima

AU - Gal-Yam, Einav

AU - Domachevsky, Liran

PY - 2023/3/1

Y1 - 2023/3/1

N2 - Purpose Invasive lobular breast cancer (ILC) may be hard to detect using conventional imaging modalities and usually shows less avidity to 18F-FDG PET/CT. 68Ga-fibroblast activation protein inhibitor (FAPI) PET/CT has shown promising results in detecting non-18F-FDG-avid cancers. We aimed to assess the feasibility of detecting metastatic disease in patients with non-18F-FDG-avid ILC. Methods This prospective study included patients with metastatic ILC, infiltrative to soft tissues, which was not 18F-FDG avid. The patients underwent 68Ga-FAPI PET/CT for evaluation, which was correlated with the fully diagnostic CT performed at the same time. Results Seven women (aged 57 ± 10 years) were included. Among the 30 organs and structures found to be involved by tumor, the number of findings observed by FAPI PET/CT was significantly higher than that observed by CT alone (P = 0.022), especially in infiltrative soft tissue and serosal locations. Conclusions This small pilot trial suggests a role for 68Ga-FAPI PET/CT in ILC, which needs to be confirmed by subsequent trials.

AB - Purpose Invasive lobular breast cancer (ILC) may be hard to detect using conventional imaging modalities and usually shows less avidity to 18F-FDG PET/CT. 68Ga-fibroblast activation protein inhibitor (FAPI) PET/CT has shown promising results in detecting non-18F-FDG-avid cancers. We aimed to assess the feasibility of detecting metastatic disease in patients with non-18F-FDG-avid ILC. Methods This prospective study included patients with metastatic ILC, infiltrative to soft tissues, which was not 18F-FDG avid. The patients underwent 68Ga-FAPI PET/CT for evaluation, which was correlated with the fully diagnostic CT performed at the same time. Results Seven women (aged 57 ± 10 years) were included. Among the 30 organs and structures found to be involved by tumor, the number of findings observed by FAPI PET/CT was significantly higher than that observed by CT alone (P = 0.022), especially in infiltrative soft tissue and serosal locations. Conclusions This small pilot trial suggests a role for 68Ga-FAPI PET/CT in ILC, which needs to be confirmed by subsequent trials.

KW - FAPI-04

KW - PET/CT

KW - breast neoplasms

KW - carcinoma

KW - lobular

UR - http://www.scopus.com/inward/record.url?scp=85147318173&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000004540

DO - 10.1097/RLU.0000000000004540

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 36638243

AN - SCOPUS:85147318173

SN - 0363-9762

VL - 48

SP - 228

EP - 232

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

IS - 3

ER -